Moderna’s COVID vaccine could sail through authorization even more smoothly than Pfizer-BioNTech’s

The few points of concern raised at the advisory committee meeting for Pfizer-BioNTech’s COVID-19 vaccine likely won't be issues for Moderna’s candidate.

Briefing documents released ahead of Thursday’s FDA advisory committee meeting to discuss Moderna’s mRNA-1273 reiterated the efficacy of the vaccine candidate, which was 94.1% across all age groups...